Ruxolitinib cream showed positive results in children 2- to 11-years-old with mild to moderate atopic dermatitis (AD), according to data of a poster presented at the American Academy of Dermatology Annual Meeting in San Diego from March 8 to 12.
Physicians switch to Opzelura (ruxolitinib) when other therapies fail to help patients with atopic dermatitis, according to a new analysis presented at the annual meeting of the American Academy of Dermatology.
John Barbieri, assistant professor at Harvard Medical School, is looking forward to the upcoming 2024 American Academy of Dermatology meeting, which runs from March 8-12 in San Diego. Barbieri is particularly showing interest in late-breaking abstracts and trial data and hoping to see cutting-edge information from pivotal clinical trials.
Amtagvi was approved to treat patients with advanced melanoma. It is a one-time cell therapy that will be administered at authorized treatment centers and have a wholesale acquisition cost of $515,000.
This makes CSU treatment the sixth approved use globally.
SkinCure Oncology has not yet submitted its data to the FDA for marketing clearance, however once cleared, the new devices will use hybrid laser-generated confocal and photoacoustic imaging in a single fused volumetric image.
The biopharmaceutical company developed VTAMA cream as a once-daily and steroid-free topical cream for both acute treatment and long-term management of AD.
The molecule, DPT0218, was detected during preclinical animal trials.
A recent survey by the American Academy of Dermatology showed that only 13% of Americans plan to use sun protection when going for walks or hikes in cold weather.
New acne guidelines from the American Academy of Dermatology recommend Winlevi (clascoterone), a topical treatment, and Seysara (sarecycline), a narrow-spectrum tetracycline, but qualify the recommendation as conditional because of concerns that the high cost may affect equitable access to treatment,
A review of published research identified only five studies. They showed that telemedicine, particularly for follow-up care, was as effective as in-person care in many respects
A recent study presents a unique case of sudden-onset vitiligo following the COVID-19 vaccination, along with a systematic review of existing literature to shed light on the potential link between vaccination and vitiligo development.
A survey of pediatric dermatologists revealed that topical corticosteroids are the most common first-line treatment for children with alopecia, regardless of age or hair loss severity.
The FDA approved Dermavant Science's Vtama (tapinarof cream) last year as a treatment for plaque psoriasis. Sales have been disappointing, according to press reports. Will Vtama, which has a different mechanism of action than the current batch of topical medications for atopic dermatitis, fare better in the atopic dermatitis market?
The FDA has set a date of July 07, 2024, for Zorvye 0.15% for adults and children six and up with the chronic skin disease atopic dermatitis.
Vtama is a steroid-free cream that works by targeting the aryl hydrocarbon receptor, which plays a role in regulating immune responses.
The updated guidelines include 11 evidence-based recommendations for the management of atopic dermatitis in adults using phototherapy and systemic treatments.
Bimzelx is the first dual IL-17 A/F inhibitor to treat moderate-to-severe plaque psoriasis. It launches with a list price of $7,200 per syringe.
Delgocitinib is first-in-class pan-Janus kinase inhibitor
Data from the study revealed that about half of the patients did not receive any treatment during their 12-month follow-up.
Almost 80% of patients in an extension study maintained clear or almost clear skin, and 90% of patients saw continued improvements in itch.
The FDA is requesting additional efficacy data to support an approval for patients with chronic spontaneous urticaria; results of an ongoing study are expected late next year.
Topline results from week 16 of a phase 3b trial demonstrated the efficacy and safety of Tremfya across all skin tones.
A European study shows that almost 1 in 5 of those with chronic skin conditions felt they were looked at with disgust.
The dosage of Zoryve for children 6 to 11 is the same as for those over the age of 12. The list price is same for both pediatrics and adults — $825 per tube.
